Clay likes to underpromise and over deliver. As it has done every quarter the outlook is super conservative. He is obviously omitting sales from Europe and Canada which can be expected to be in the same order of magnitude as that in the US given the bigger sum of the poulation in both area.
At some point WS will catch on to him. Until then the traders will continue to sell SGEN off after every quarterly report but the investors will not care since share price still grows ~ 50% each year.
This is baloney, the analyst at bofA got it right. Q4 sales already include off label sales. No growth from 3Q, and all these existing sales included off label. 2013 is set lower than 2012 at $130m to $140M, these must include off label assumptions even if conservative, a price increase even if conservative and Canada sales. How can one claim that the guidance do not include off label when your quarter sales do include them? Even taking a modest growth quarter over quarter one ends up with something higher than $140M. They are either way too conservative and losing credibility or actually losing patients. What are the current indication peak sales ($150M)? Have we reach this after less than 2 years in the market. This is a real stincker.